Cerus (NASDAQ:CERS) Stock Rating Lowered by Wall Street Zen

Cerus (NASDAQ:CERS) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, TD Cowen reaffirmed a “buy” rating on shares of Cerus in a report on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cerus presently has a consensus rating of “Hold”.

Cerus Trading Down 5.4%

Shares of NASDAQ CERS opened at $1.93 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.73 and a debt-to-equity ratio of 0.62. The stock’s 50 day moving average price is $2.31 and its two-hundred day moving average price is $1.84. Cerus has a 52-week low of $1.12 and a 52-week high of $2.95. The stock has a market capitalization of $370.89 million, a P/E ratio of -24.13 and a beta of 1.51.

Cerus (NASDAQ:CERS) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The company had revenue of $64.58 million during the quarter, compared to analyst estimates of $59.31 million. On average, analysts anticipate that Cerus will post -0.08 earnings per share for the current fiscal year.

Institutional Trading of Cerus

Several hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its position in Cerus by 321.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 46,801 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 35,692 shares in the last quarter. Invesco Ltd. raised its position in shares of Cerus by 28.8% during the 4th quarter. Invesco Ltd. now owns 309,168 shares of the biotechnology company’s stock worth $637,000 after buying an additional 69,087 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Cerus by 48.6% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 53,028 shares of the biotechnology company’s stock worth $109,000 after buying an additional 17,336 shares in the last quarter. Engineers Gate Manager LP lifted its stake in shares of Cerus by 4.7% in the 4th quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 6,415 shares during the period. Finally, Kotler Kevin acquired a new stake in shares of Cerus in the 4th quarter worth approximately $2,084,000. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.